Global Plasma Therapy Market

1 INTRODUCTION OF GLOBAL PLASMA THERAPYMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PLASMA THERAPYMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL PLASMA THERAPY MARKET, BY END USER
5.1 Hospitals & Clinics
5.2 Research Institutes

6 GLOBAL PLASMA THERAPY MARKET, BY APPLICATION
6.1 Cardiac Muscle Injury
6.2 Dental
6.3 Nerve Injury
6.4 Dermatology
6.4.1 Plastic Surgery
6.4.2 Androgenic Alopecia
6.5 Orthopedic
6.5.1 Arthritis
6.5.2 Chronic Tendinitis
6.5.3 Bone Repair & Regeneration
6.6 Others

7 GLOBAL PLASMA THERAPY MARKET, BY SOURCE
7.1 Autologous
7.2 Allogenic

8 GLOBAL PLASMA THERAPY MARKET, BY TYPE
8.1 Pure PRP
8.2 Leukocyte-Rich PRP
8.3 Pure Platelet-Rich Fibrin
8.4 Leukocyte-Rich Fibrin

9 GLOBAL PLASMA THERAPYMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

10 GLOBAL PLASMA THERAPYMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES
11.1 Biolife Plasma Services
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments

11.2 CordlifeCordlife
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments

11.3 Biotest
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments

11.4 CSL Ltd.
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments

11.5 Grifols International S.A.
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments

11.6 Kedrion S.P.A.
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments

11.7 LFB SA
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments

11.8 Bio Product Laboratory Ltd. (BPL)
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments

11.9 China Biologic Products, Inc.
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Development

11.10 Octapharma
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Development

12 Appendix
12.1 Related Reports